---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280658122.md"
description: "Pulmatrix shares are trading lower after the company announced it will acquire Eos, a developer of novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases."
datetime: "2026-03-26T15:10:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280658122.md)
  - [en](https://longbridge.com/en/news/280658122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280658122.md)
generator: "portal-rs"
---

# 

Pulmatrix shares are trading lower after the company announced it will acquire Eos, a developer of novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PULM.US](https://longbridge.com/en/quote/PULM.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)
- [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**